Cargando…
AG488 as a therapy against gliomas
High-grade gliomas such as glioblastomas (GBM) present a deadly prognosis following diagnosis and very few effective treatment options. Here, we investigate if the small molecule AG488 can be an effective therapy against GBM with both anti-angiogenic as well as an anti-microtubule inhibiting modalit...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641093/ https://www.ncbi.nlm.nih.gov/pubmed/29069750 http://dx.doi.org/10.18632/oncotarget.18284 |
_version_ | 1783271157762359296 |
---|---|
author | Ziegler, Jadith Bastian, Anja Lerner, Megan Bailey-Downs, Lora Saunders, Debra Smith, Nataliya Sutton, Jake Battiste, James D. Ihnat, Michael A. Gangjee, Aleem Towner, Rheal A. |
author_facet | Ziegler, Jadith Bastian, Anja Lerner, Megan Bailey-Downs, Lora Saunders, Debra Smith, Nataliya Sutton, Jake Battiste, James D. Ihnat, Michael A. Gangjee, Aleem Towner, Rheal A. |
author_sort | Ziegler, Jadith |
collection | PubMed |
description | High-grade gliomas such as glioblastomas (GBM) present a deadly prognosis following diagnosis and very few effective treatment options. Here, we investigate if the small molecule AG488 can be an effective therapy against GBM with both anti-angiogenic as well as an anti-microtubule inhibiting modalities, using a human G55 glioma xenograft model in nude mice. From in vitro studies, we report that AG488 incubation reduced cell viability in G55 and HMEC-1 cells more so than TMZ treatment, and AG488 treatment also decreased cell viability in normal astrocytes, but not as much as for G55 cells (p<0.0001). In vivo investigations indicated that AG488 therapy helped reduce tumor volumes (p<0.0001), prolong survival (p<0.01), increase tumor perfusion (p<0.01), and decrease microvessel density (MVD) (p<0.05), compared to untreated mice or mice treated with non-specific IgG, in the G55 xenograft model. Additionally, AG488 did not induce apoptosis in normal mouse brain tissue. Animal survival and tumor volume changes for AG488 were comparable to TMZ or anti-VEGF therapies, however AG488 was found to be more effective in decreasing tumor-related vascularity (perfusion and MVD). AG488 is a potential novel therapy against high-grade gliomas. |
format | Online Article Text |
id | pubmed-5641093 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-56410932017-10-24 AG488 as a therapy against gliomas Ziegler, Jadith Bastian, Anja Lerner, Megan Bailey-Downs, Lora Saunders, Debra Smith, Nataliya Sutton, Jake Battiste, James D. Ihnat, Michael A. Gangjee, Aleem Towner, Rheal A. Oncotarget Research Paper High-grade gliomas such as glioblastomas (GBM) present a deadly prognosis following diagnosis and very few effective treatment options. Here, we investigate if the small molecule AG488 can be an effective therapy against GBM with both anti-angiogenic as well as an anti-microtubule inhibiting modalities, using a human G55 glioma xenograft model in nude mice. From in vitro studies, we report that AG488 incubation reduced cell viability in G55 and HMEC-1 cells more so than TMZ treatment, and AG488 treatment also decreased cell viability in normal astrocytes, but not as much as for G55 cells (p<0.0001). In vivo investigations indicated that AG488 therapy helped reduce tumor volumes (p<0.0001), prolong survival (p<0.01), increase tumor perfusion (p<0.01), and decrease microvessel density (MVD) (p<0.05), compared to untreated mice or mice treated with non-specific IgG, in the G55 xenograft model. Additionally, AG488 did not induce apoptosis in normal mouse brain tissue. Animal survival and tumor volume changes for AG488 were comparable to TMZ or anti-VEGF therapies, however AG488 was found to be more effective in decreasing tumor-related vascularity (perfusion and MVD). AG488 is a potential novel therapy against high-grade gliomas. Impact Journals LLC 2017-05-30 /pmc/articles/PMC5641093/ /pubmed/29069750 http://dx.doi.org/10.18632/oncotarget.18284 Text en Copyright: © 2017 Ziegler et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Research Paper Ziegler, Jadith Bastian, Anja Lerner, Megan Bailey-Downs, Lora Saunders, Debra Smith, Nataliya Sutton, Jake Battiste, James D. Ihnat, Michael A. Gangjee, Aleem Towner, Rheal A. AG488 as a therapy against gliomas |
title | AG488 as a therapy against gliomas |
title_full | AG488 as a therapy against gliomas |
title_fullStr | AG488 as a therapy against gliomas |
title_full_unstemmed | AG488 as a therapy against gliomas |
title_short | AG488 as a therapy against gliomas |
title_sort | ag488 as a therapy against gliomas |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641093/ https://www.ncbi.nlm.nih.gov/pubmed/29069750 http://dx.doi.org/10.18632/oncotarget.18284 |
work_keys_str_mv | AT zieglerjadith ag488asatherapyagainstgliomas AT bastiananja ag488asatherapyagainstgliomas AT lernermegan ag488asatherapyagainstgliomas AT baileydownslora ag488asatherapyagainstgliomas AT saundersdebra ag488asatherapyagainstgliomas AT smithnataliya ag488asatherapyagainstgliomas AT suttonjake ag488asatherapyagainstgliomas AT battistejamesd ag488asatherapyagainstgliomas AT ihnatmichaela ag488asatherapyagainstgliomas AT gangjeealeem ag488asatherapyagainstgliomas AT townerrheala ag488asatherapyagainstgliomas |